AbbVie Inc (ABBV)vsAlpha Cognition Inc (ACOG)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ACOG
Alpha Cognition Inc
$5.82
-1.52%
HEALTHCARE · Cap: $138.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 580193% more annual revenue ($62.82B vs $10.83M). ABBV leads profitability with a 5.8% profit margin vs -234.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ACOG
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ACOG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Revenue surging 20.7% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -43.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ACOG
The strongest argument for ACOG centers on Price/Book, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ACOG
The primary concerns for ACOG are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while ACOG is a growth play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.39 — expect wider price swings.
ACOG is growing revenue faster at 20.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a forward-thinking biopharmaceutical company dedicated to pioneering innovative therapies for neurodegenerative conditions, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, targets cognitive enhancement, addressing significant unmet needs within the aging demographic. By harnessing a proprietary neuroscience platform and robust research and development initiatives, Alpha Cognition is positioned to drive advancements in patient care. As the company advances its clinical pipeline and explores additional therapeutic avenues, it represents a compelling investment prospect for institutional investors seeking exposure to transformative innovations in the healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?